Cite
HARVARD Citation
Cohen, S. et al. (2017). Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. Annals of the rheumatic diseases. 76 (10), pp. 1679-1687. [Online].